Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2-positive Breast Cancer 1 HER2 Overexpression 1

Interventions

Trastuzumab 33 pertuzumab 18 Docetaxel 16 pyrotinib 15 Paclitaxel 7 Capecitabine 6 tucatinib 5 Carboplatin 5 Ado-Trastuzumab Emtansine 4 trastuzumab deruxtecan 3 neratinib 3 atezolizumab 2 Protons 2 Neoadjuvant Therapy 2 Fulvestrant 2 pegfilgrastim 1 palbociclib 1 margetuximab 1 liposomal doxorubicin 1 inavolisib 1 exemestane 1 envafolimab 1 dalpiciclib 1 Taxoids 1 Metformin 1 Leuprolide 1 Letrozole 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Hospital Information Systems 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × Isovaleryl-CoA Dehydrogenase × Clear all

NCT07281001 2025-12-15

Traderrus

Blokhin's Russian Cancer Research Center

Phase NA Recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡